Dihua Yu

Dihua Yu, M.D., Ph.D., is a tenured Professor and Chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX. He also holds the prestigious Hubert L. & Olive Stringer Distinguished Chair in Basic Science. Additionally, he serves as faculty at the Graduate School of Biomedical Sciences (GSBS) at The University of Texas Health Science Center, Houston, reflecting his dual institutional affiliation and commitment to advanced biomedical training.

Dr. Yu's research is centered in the field of molecular and cellular oncology, with a strong emphasis on understanding the fundamental mechanisms driving cancer development and progression. His work bridges basic science discoveries with translational applications, particularly in breast cancer and metastasis. As Chair of a major discovery science division, his leadership supports cutting-edge research in cancer signaling, tumor biology, and genomic instability.

Although specific publications are not listed in the provided text, the breadth of his research areas suggests a focus on signal transduction pathways, oncogenes, tumor suppressors, and the molecular basis of cancer metastasis. His work likely contributes significantly to the development of novel therapeutic strategies.

Dr. Yu has received notable recognition, including the Hubert L. & Olive Stringer Distinguished Chair in Basic Science, highlighting his impact in cancer research. While specific awards and honors are not enumerated, this named chair is a testament to his scientific excellence.

He plays a key role in mentoring the next generation of scientists through his involvement with the Graduate School of Biomedical Sciences. His leadership extends to grant and contract-supported research, though specific funding sources are not detailed. As Chair, he oversees a large research department involved in fundamental cancer discovery.

Dr. Yu is actively leading research initiatives within MD Anderson’s Division of Discovery Science, contributing to one of the world’s leading cancer research institutions. His lab and team are likely engaged in high-impact projects aimed at uncovering new targets for cancer therapy and improving patient outcomes through molecular insights.